Caldan Therapeutics is focused on developing innovative therapies that target the underlying mechanisms of disease, particularly in the field of cancer and autoimmune disorders. The company employs a proprietary platform that leverages advanced drug discovery techniques to identify and optimize small molecules. This platform is designed to enhance the specificity and efficacy of therapeutic candidates, allowing for more effective treatment options with potentially fewer side effects. Caldan's pipeline includes several promising candidates that are currently in various stages of preclinical and clinical development, showcasing the company's commitment to addressing unmet medical needs.

In addition to its drug discovery platform, Caldan Therapeutics emphasizes the importance of a deep understanding of the biological pathways involved in disease progression. The company integrates cutting-edge technologies such as high-throughput screening and computational modeling to facilitate the identification of novel drug targets. By combining these approaches with rigorous scientific research, Caldan aims to accelerate the development of its therapeutic candidates and bring innovative solutions to patients suffering from challenging health conditions.

United Kingdom

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing
novel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.

Caldan Therapeutics

Company Details